619 First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: updated phase 1 results
Main Authors: | Shivaani Kummar, Drew Rasco, Scott A Laurie, Dylan M Glatt, Sophia R Majeed, Albiruni Abdul Razak, Anh Diep |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies
by: Maike Schmidt, et al.
Published: (2023-11-01) -
23ME-00610, a genetically informed, first-in-class antibody targeting CD200R1 to enhance antitumor T cell function
by: Jill Fenaux, et al.
Published: (2023-12-01) -
Anti-Allergic Compounds from the Deep-Sea-Derived Actinomycete Nesterenkonia flava MCCC 1K00610
by: Chun-Lan Xie, et al.
Published: (2017-03-01) -
Increasing patient participation in oncology clinical trials
by: Jie Chen, et al.
Published: (2023-02-01) -
AGW 619 - CORPORATE FINANCE APRIL 08.
by: PPP, Pusat Pengajian Pengurusan
Published: (2008)